Image

Summary

The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.

Biosimilars Forum 2019 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.

Join us in Brazil and trigger a quantum leap in Latin American Healthcare!

Who will
you meet?

More than:

 

0
Participants
0
Companies

Directors

VP's

CEO's

COO's

Bio-technologists

Managing Directors

Managers and Specialists

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance

Speakers

Adilson Montaneira

Adilson Montaneira

Pfizer, Brazil. Business Unit Director - Biosimilar Read More
Eduardo Cioppi

Eduardo Cioppi

mAbxience, Argentina. Regional Director - Latin America Read More
Francisco Kuri

Francisco Kuri

Landsteiner, Mexico. New Developments Director Read More
Marcelo Nogueira

Marcelo Nogueira

Novartis, Brazil. Latam, CA and Canada Compliance Monitor Read More
Mauricio Rubio

Mauricio Rubio

Colombia. Life Sciences & Pharmaceutical BDE Read More
  • 1
  • 2
  • 3
  • 4

Programme at a Glance

Regulatory Update - Brazil
Best Practice: How to get move a biosimilar in an emerging market?
Regulatory Agencies´ Efforts to Increase Biosimilars Access in Latam
Risk Management Plan - Pharmacovigilance in Latam
Tailoring Pharmacovigilance to Changing Regulatory Standards
Panel: How Can Regulation on Biosimilars be Consolidated in the Region?
Challenges and Opportunities for the Legal and Compliance Environment of Biosimilars in Latin America.
Panel: The Latam Industry Approach
Panel: Evaluating the 5+ Years of PDP Project
Is traceability useful for interchangeability?
Panel with leaders: What the Future of Biosimilars Is?
Full programme in the PDF Agenda

Highlights from Biosimilars Latam 2018, Mexico

Keep me updated



About "JackLeckerman"

JackLeckerman Company has been established as a business intelligence event services and the promotion of global summits, strategic conferences, open forums and professional training.

©2019 JackLeckerman. All Rights Reserved. Designed By

Search